- AnaptysBio press release ( NASDAQ: ANAB ): Q4 GAAP EPS of -$0.93.
- Revenue of $6.8M (+580.0% Y/Y).
- Cash, cash equivalents and investments totaled $584.2 million as of December 31, 2022, compared to $615.2 million as of December 31, 2021, for a decrease of $31.0 million.
- Research and development expenses were $23.4 million and $88.8 million for the three and twelve months ended December 31, 2022, compared to $26.8 million and $98.5 million for the three and twelve months ended December 31, 2021
- Non-cash interest expense was $4.3 million and $21.1 million for the three and twelve months ended December 31, 2022, compared to $1.5 million for the three and twelve months ended December 31, 2021.
For further details see:
AnaptysBio GAAP EPS of -$0.93, revenue of $6.8M